Abnormal M1/M2 macrophage phenotype profiles in the small airway wall and lumen in smokers and chronic obstructive pulmonary disease (COPD) by Eapen MS et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Eapen MS, Hansbro PM, McAlinden K, Kim RY, Ward C, Hackett T-L, Walters 
EH, Sohal SS. Abnormal M1/M2 macrophage phenotype profiles in the small 
airway wall and lumen in smokers and chronic obstructive pulmonary disease 
(COPD). Scientific Reports 2017, 7(1), 13392. 
 
Copyright: 
This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative 
Commons license, and indicate if changes were made. The images or other third party material in 
this article are included in the article’s Creative Commons license, unless indicated otherwise in a 
credit line to the material. If material is not included in the article’s Creative Commons license and 
your intended use is not permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a copy of this license, visit 
http://creativecommons.org/licenses/by/4.0/ 
 
DOI link to article: 
https://doi.org/10.1038/s41598-017-13888-x 
Date deposited:   
07/11/2017 
1SCIENTIFIC RepoRts | 7: 13392  | DOI:10.1038/s41598-017-13888-x
www.nature.com/scientificreports
Abnormal M1/M2 macrophage 
phenotype profiles in the small 
airway wall and lumen in smokers 
and chronic obstructive pulmonary 
disease (COPD)
Mathew Suji Eapen  1, Philip M. Hansbro3, Kielan McAlinden4, Richard Y. Kim3, Chris Ward5, 
Tillie-Louise Hackett6, Eugene H. Walters1 & Sukhwinder Singh Sohal1,2
We explore potential dysregulation of macrophage phenotypes in COPD pathogenesis through 
integrated study of human small airway tissue, bronchoalveolar lavage (BAL) and an experimental 
murine model of COPD. We evaluated human airway tissue and BAL from healthy controls, 
normal lung function smokers (NLFS), and COPD subjects. Both small airways and BAL cells were 
immunohistochemically stained with anti-CD68 for total macrophages and with anti-CD163 for M2, 
and anti-iNOS for M1 macrophages. Multiplex ELISA measured BAL cytokines. Comparable cigarette 
smoke-induced experimental COPD mouse model was assessed for relevant mRNA profiles. We found 
an increase in pro-inflammatory M1s in the small airways of NLFS and COPD compared to controls with 
a reciprocal decrease in M2 macrophages, which remained unchanged among pathological groups. 
However, luminal macrophages showed a dominant M2 phenotype in both NLFS and COPD subjects. 
BAL cytokine skewed towards an M2 profile with increase in CCL22, IL-4, IL-13, and IL-10 in both NLFS 
and COPDs. The mouse-model of COPD showed similar increase in mRNA for M2 markers. Our finding 
suggests abnormal macrophage switching in both mucosal and luminal areas of COPD patients, that 
strongly associated with cytokine balance. There may be potential for beneficial therapeutic cytokine 
manipulation of macrophage phenotypes in COPD.
Airflow limitation is the defining feature of COPD and is due primarily to small airway wall fibrosis, thickening, 
and luminal narrowing and progressive obliteration. These events occur early in disease even before symptoms 
appear or lung function changes1. Further, emphysema may occur in some COPD individuals, which also adds to 
airflow limitation2. Airway inflammation has become accepted as the key underlying driver of COPD pathophysi-
ological manifestations, but with limited core evidence, at least for the airway wall rather than the lumen3. We and 
others have suggested that the role of inflammation in COPD requires reassessment, especially in earlier stages of 
disease where rather paradoxically hypo-cellularity4–6 and an overall decrease in inflammatory cell numbers7 has 
recently been described in both the large and small airway wall in COPD patients.
Increases in the total numbers of macrophages in the airway lumen have been well established in smokers 
and COPD patients8–10. We recently assessed small airway wall tissue for CD68 + macrophages, and although, we 
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found a greater number of macrophages in the small airway wall in normal controls compared to the large airway, 
there were no changes in their numbers in smokers or COPD3,5.
Macrophages can exhibit polarized phenotypes, with, M1 and M2 subpopulations reflecting the paradigm of 
Th1 and Th2 lymphocytes11. M1 macrophages have been described as cytotoxic and pro-inflammatory, and are 
characterized by secretion of the cytokines interferon (IFN)-γ and IL-12, and by promoting Th1-type immu-
nity11–13. In contrast, M2 macrophages are considered anti-inflammatory and are linked to tissue repair and fibro-
sis, secreting pro-Th2 cytokines including CCL22, IL-4, IL-13 and IL-10 14.
Macrophages have a fundamental ability to metabolize L-arginine either to nitric oxide (NO) or ornithine, 
using the mutually substrate-competitive enzymes inducible nitric-oxide synthase (iNOS) or arginase-I (Arg-1), 
respectively12. Phenotypically M1 macrophages exhibit increased iNOS expression, while M2 macrophages are 
typified by an increase in Arg-1, which promotes collagen synthesis by making the amino acid proline available 
to fibroblasts15,16. The competition between iNOS and Arg-1 for L-arginine can drive contrasting pathologies 
functionally through opposed macrophage phenotypes17.
In the current study, we have characterized the phenotypic and metabolic regulatory dichotomy of airway wall 
macrophage populations and their micro-environments in human lung tissue and bronchoalveolar lavage (BAL), 
and related phenotype is switching to smoking, COPD, and lung function. We further confirmed these findings 
in a six-week cigarette smoke-induced mouse model of experimental COPD.
Results
M1/M2 phenotypes in small airways. In the small airway epithelium, the dominant macrophage type 
both in numbers and percentages was the non-differentiated M0, especially in normal control (NC) subjects 
(Fig. 1a,c), where there were essentially very few M1 (median percenatge 0%; range 0–5.2) macrophages. There 
was a significant increase in percent M1 population in normal lung function smokers (NLFS) [median perce-
natge18%; range 0–100; (p < 0.05)] and COPD current smoker (COPD-CS) [median percentage 21.2% range 
0.0–64.1; (p < 0.01)], which reverted partially towards normal in COPD ex-smokers (COPD-ES) [median per-
centage 10% range 0.0–42; (p < 0.05)] (Fig. 1c). Small numbers and percentage of M2 macrophages were present 
in the NC (median percentage 6.4%; range 0.0–43.3) but were almost absent in NLFS [median percenatge 0%; 
Figure 1. Macrophages phenotype numbers in SA tissue. In epithelium: an increase in the numbers of (a) M1 
and a decrease in (b) M2 macrophages observed in smokers and COPDs compared to NC. Similar pattern was 
also observed in the sub-epithelium (d) M1 and (e) M2. Percent change in macrophage phenotypes M0, M1 and 
M2 in (c) Epithelium and (f) Sub-epithelium expression (Data in median and range; *p < 0.05, **p < 0.01).
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range 0.0–9.0 (p < 0.05)], COPD-CS [median percentage 0%; range 0.0–0.01 (p < 0.01)] and COPD-ES [median 
percentage 0%; range 0.0–10.1 (p < 0.05)] (Fig. 1b and c).
In the subepithelium in NC, the M0 population was less dominant than in the epithelium, with relatively fewer 
M1s (median percentage 1.6%; range 0.0–6.3) and more M2 macrophages (median 36%; range 0.0–63) (Fig. 1f). 
A significant rise in the M1 population was observed in the NLFS [median percenatge 10.1%; range 0.0–60.2 
(p < 0.01)] and COPD-CS [median percenatge 9.6% range 1.6–48 (p < 0.05)]. There were declines compared to 
normal in the M2 population in smokers (median percentage 23% range 0.0–64.1) and COPD, again especially 
significant in COPD-CS [median percentage 8.4%;range 0.0–19.9 (p < 0.01)] (Fig. 1f). No statistical significant 
difference was observed between NLFS and COPD-CS.
A descriptive illustration comparing the macrophage sub-population phenotypes in NC and COPD-CS is 
represented in Fig. 2.
Further, there was a positive correlation between smoking pack-years and increase in M1 macrophages in the 
epithelium (Pearsons r = 0.55, p = 0.006) (Fig. 3a.) while a negative correlation was observed for sub-epithelial 
M2 macrophages (Pearsons r = −0.46, p = 0.02) (Fig. 3b).
Arginase-1 (Arg-1) expression in the SA wall. The small airways wall tissue of COPD patient-CSs 
showed a marked overall non-specific increase in tissue expression of Arg-1, both in epithelium (p < 0.01) and 
subepithelium (p < 0.001) in comparison to normal controls (Fig. 4). At this stage we have not quantified this in 
non-COPD smokers, but descriptively the staining is present but less abundant.
AM phenotypes in the Bronchoalveolar lavage (BAL). When comparing the alveolar macrophages 
within the alveolar spaces (Fig. 5a–c) of resected lung tissue (also containing small airways) of COPD patients, we 
observed similarity in both morphological and M1/ M2 expression patterns with luminal macrophages derived 
from BAL lumen (Fig. 6b,d and f). However, we have provided here only the quntitative results frrom mac-
rophages from the BAL samples. A two to three-fold increase in total BAL CD68 + AMs was found in NLFS 
(p < 0.01) and COPD-CS (p < 0.05), while in COPD-ES they were similar to normal levels (Fig. 7a). Unlike the 
tissue macrophage data, there was fewer undifferentiated percent M0 AMs across the groups (Fig. 7d).
Figure 2. Representative micrographs of M1 macrophages dual stained for iNOS (brown) and CD68 (blue). (a) 
Thin epithelium and thin walled normal control, (b) thick epithelium and thick walled COPD-CS, 
counterstained with nuclear fast red (pink). ( ) Dual stained CD68 + iNOS + cells, ( ) only CD68 + cells. 
CD163 staining M2 macrophages (c) NC (d) COPD-CS.
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The BAL AMs in NC were predominantly M1 (median percentage 66.3%; range 31.5–91.2) with essentially 
fewer M2s (median percentage 0% range 0.0–42.7) (Fig. 7d). There was a marked change in phenotype profiles 
in the clinical groups, with a decrease in the percent of M1 (median percentage 26.3%; range 0.1–53.1) in NLFS, 
COPD-CS (median percentage 40.4%; range 6.2–82.5) and ES (median percentage 33.6%; range 4.0–80) and 
increases in M2 macrophages (median percentage 49.5%; range 31.5–91.2) in NLFS, COPD-CS (median percent-
age 27.15%; range 0.2–71.9) and COPD-ES (median percentage 21.9%; range 1.3–72.7) (Fig. 5d).
Both total CD68 + AMs (Spearman’s rho (rs) = −0.35, p =  < 0.05) and M2 AMs (Spearman’s rho (rs) = −0.5, 
p < 0.01) (Fig. 8a and b) correlated negatively with FEV1/FVC.
BAL M2-associated cytokines were increased in COPD. A marked increase in M2-related MDC/
CCL22, IL-4, IL-13, and IL-10 was observed in the BAL supernatants from NLFS and COPD subjects (Fig. 9a), 
with a decrease in the M1-related cytokine IL-12p40 but not for IFN-γ (Fig. 9b). We also found a significant 
increase in the pleiotropic cytokine IL-6 in both smoker and COPD groups (Fig. 9c). Further, a small but signifi-
cant increase in proinflammatory IL-1β was observed in smokers but not in COPD while for TNFα there was an 
increase only in COPD-CS compared to normal controls (Fig. 9c). An increase in the ratio of IL-12p40 to IL-4 
(M1/M2 cytokines) confirmed the switch to M2 dominance in BAL COPD-CS (Fig. 9d). There was a positive 
correlation in COPD-CS between CCL22 and IL-4 and M2 macrophage numbers (Fig. 10 a and b).
Whole mouse COPD lung mRNA expression. We confirmed a similar pattern of M2 cytokine mRNA 
predominance in a well-established mouse model of chronic cigarette smoke exposure that is representative 
of exposure in a pack-a-day smoker13,18–24. We found with upregulation for CCL22 (fold change [FC] = 1.718; 
p = 0.012), IL-4Rα (FC = 1.270; p = 0.018), and IL-13Rα1 (FC = 1.673; p = 0.018), while there were no changes 
for M1-related iNOS/NOS2, IL-12 or IP-10 mRNAs (Fig. 11).
Discussion
This study is the first to phenotypically differentiate small airway wall and airway lumen macrophage subpopula-
tions based on their M1 and M2 phenotypes in normal, smokers and COPD patients. Our observations suggest 
dynamic differential switching in both the small airways and BAL AMs, but qualitatively these were quite differ-
ent. In small airways, there was a switch towards a predominantly M1 phenotype in both NLFS and COPD-CS 
compared to to NC (Fig. 2) that suggests a smoking effect, while, in BAL AMs there was a switch towards M2 
dominance (Fig. 6). Further, cytokines in BALF from smokers and COPD-CS were skewed towards a M2 profile. 
Data obtained from a chronic cigarette smoke-induced murine model also suggested that an M2 milieu in the 
present in whole lung tissue.
M1 and M2 macrophages are considered to be functionally differentiated, with M1 more pro-inflammatory 
and M2 more pro-fibrotic. For the M1 phenotyping, we chose iNOS + as a marker25 with CD68 co-staining to 
differentiate them from other iNOS producing cells such as dendritic and natural killer (NK) cells. For M2 we 
used CD163, which is a scavenger receptor that is upregulated in a more TH2 microenvironments10,26. Whether 
the different phenotypic skewing is a compartmental effect or caused by the movement of differentiated cells from 
wall to lumen needs further investigation. We believe that it is most likely the former as there was no gradient 
towards the lumen from sub-epithelium to epithelium, and there was no reciprocal decrease in wall cell numbers 
contributing to the significant increase in luminal macrophages.
Figure 3. Regression analysis for tissue macrophage phenotypes with pack year history for NLFS and 
COPD-CS for (a) epithelial M1 and (b) sub-epithelial M2 macrophages.
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The normal predominance of iNOS-expressing M1 macrophages occurs to fight pathogens through luminal 
production of nitric oxide (NO), an innate immune effector. However, such a response is non-specific, and when 
uncontrolled can cause considerable damage to host tissues and cells. Our observation of reduced percent M1 
macrophages in the airway wall in COPD current and ex-smokers compared to normal lung function smokers, 
therefore, suggests a reduced ability fight infection27. It may also reflect homeostatic adaptation to avoid excessive 
tissue damage. Recent evidence suggests that elevated levels of NO inherently suppress the M1 phenotype28.
Given the iNOS changes, we also wished to investigate the functionally reciprocal Arg-1. Interestingly, we 
found a higher non-specific expression of Arg-1 throughout the airway wall mucosa including epithelium, 
sub-epithelium and alveolar septae in COPD-CS compared to normal non-smoker controls. This overexpression 
of Arg-1 could be the consequence of increased cellular catabolic activity, associated with increased oxidative 
stress in smokers, catalyzing L-arginine to urea and L-ornithine via urea cycle. L-ornithine is a known precursor 
to L-proline, a key amino acid in the biosynthesis of collagen, and associated with wound healing15. The excess 
deposition of collagen, however, leads to airway wall stiffness of the small airways, an important pathophysio-
logical feature in COPD29. Further, exhaled NO is also well known to be decreased in smokers, but the reason for 
this has been unclear30,31.
Our finding of an M2 predominance in the airway luminal macrophages in smokers with and without COPD 
are resonant of two previous studies, although they found an increase percentage of M2 AMs only in COPD-ex 
smokers10,32. One study32 lacked normal control BAL, and neither assessed the M1 phenotype populations. Our 
findings are in line with the study by Shaykhiev et al.33, where gene expression analysis of cytokines and chemok-
ines revealed more M2-polarised AMs in smokers and COPD compared to non-smoking controls. Further, our 
increase in both total AMs and especially M2 macrophage subtypes correlated to airflow obstruction, suggesting 
biological plausibility.
Figure 4. Arginase-1 expression in the small airway wall of (a) NC compared to (b) COPD-CS. A significant 
increase in Arginase-1 expression was observed in both (c) epithelium and (d) sub-epithelium. Data are 
presented as median and range; group comparisons with Mann-Whitney two-tailed t-test; p < 0.05 was 
considered significant.
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Our BAL cytokine data reflect the cellular phenotype switching that we observed in that compartment. IL-4 
and IL-13 share a common receptor, IL-4Rα/IL-13Rα1, which signals via the JAK-1/STAT6 pathway, to induce 
differentially-activated M2 macrophages34. Studies by Rutschman et al.35, showed that the induction of the STAT6 
pathway by IL-4 and IL-13 suppressed iNOS expression, and so NO production, by post-transcriptional modi-
fication. Other studies have also demonstrated that IL-4, IL-13, and IL-10 also synergistically upregulate Arg-1 
expression in macrophages36. Our current study indirectly corroborates all these findings, but now in humans 
with the clinical disease.
We also observed an increase in CCL22 in BAL in NLFS and COPD. CCL22 is a regulatory chemokine 
secreted by M2 macrophages in response to TH2 polarized cytokines such as IL-4, IL-5, and IL-13, while it is 
downregulated by the TH-1 cytokine IFNγ37,38. Importantly, given the common co-association of COPD and lung 
cancer, CCL22 has been implicated in tumorigenesis. Its active secretion by M2 tumor-associated macrophages 
(TAMs) is known to promote malignancy by inhibiting suppressor T cell recruitment. Similar tumorigenic effects 
have been attributed to IL-6, which we also found to be elevated in smokers and COPD. Further, in vitro studies 
in macrophages also suggested that IL-6 promotes an M2 phenotype and increased M2-associated markers such 
as Arg-139.
The differences in the polarization of macrophage subtypes between small airways and lumen were marked. 
This suggests a difference in the cytokine milieu in each anatomic microenvironment, promoting a shift towards 
the M1 phenotype in the airway wall but towards M2 in the airway lumen. This may have important implica-
tions for the distinct pathologies observed in each site in COPD disease, i.e. infection and ROS-induced innate 
immune activation in the lumen, but fibrosis and thickening of the airway wall. However, there are limita-
tions to the current study, with tissue originating from two separate patient groups with BAL from COPD-CS, 
COPD-ex-smokers, NLFS and NC and small airway resections from similar physiological cohorts but cancer 
patients. Thus, it is possible that the macrophage phenotypes and cytokine profile is possibly influenced by the 
presence of cancer but we have quantified the airway wall tissue macrophages well away from cancerous areas.
We further investigated whether our human findings could be confirmed in a mouse smoking model and 
evaluated the mRNA levels in whole lung tissue of mice with cigarette smoke-induced experimental COPD. 
Interestingly, after six-weeks of smoke exposure, which represents an early stage of disease pathogenesis, mouse 
lung data confirmed the human findings, with specific M2 phenotypic mRNA for CCL-22, IL-4Rα, and IL-13α, 
with no changes in mRNA for M1 markers iNOS, IL-12p40 and IP-10. Our findings are currently limited to the 
mRNA from whole lung tissue and thus, unlike the human data, are not compartmentalized. However, we believe 
that the addition of mouse data in the current study strengthens our human findings and will be an impetus to our 
future mechanistic and interventional mouse studies about macrophage function.
Conclusion
The major novel findings in this study are the reduction in M2 and increase in M1 macrophages in the airway wall 
of SAs in smokers and COPD. M1 are the strongest signal for innate inflammatory up-regulation we have seen 
in the airway wall to date. The finding of an M2 switch in BAL in smokers with and without COPD was in stark 
contrast to the macrophage phenotype in the small airway wall. BALF cytokine profiling revealed promotion of 
an M2 phenotype. The switching was confirmed in lung tissue from a chronic smoking mouse model. The overall 
tissue expression of Arg-1 in the SA wall suggests increased catabolic activity, a sign of cellular senescence but 
could also have implication for in lung fibrosis and airway resistance. These novel findings are potentially impor-
tant in understanding the pathophysiology of the respiratory tract’s response to smoking and in the etiology of 
COPD; they need to be taken into account when considering mostly unexplained cellular functional phenomena 
associated with COPD, and the specific vulnerability of COPD sufferer to lung cancer.
Methods
Ethics approval. The Tasmanian Health & Medical Human Research Ethics Committee approved the 
study (EC00337- Small Airway resected tissue and H6532 – BAL fluid samples). Informed consent were directly 
Figure 5. Expression patterns of alveolar macrophages (AMs) in the alveolar spaces in resected tissue of 
COPD patients (200x), (a) M1 AMs dual stained for iNOS (brown) and CD68 (blue), counterstained with 
nuclear fast red (pink), M2 phenotype macrophages stained brown with (b) CD163 and (c) arginase-1(ARG-1), 
counterstained with nuclear-stained hematoxylin (blue).
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obtained from all participating subjects. The Animal Ethics Committee of The University of Newcastle, Australia 
approved all mouse related protocols. All experiments included in this study are in accordance to the relevant 
institutional guidelines and regulations.
Subject classification. SA resected tissues. Forty patients consented for inclusion in this study Table 1. 
Subjects all had primary non-small cell lung cancer, with an approximately equal distribution of squamous and 
adenocarcinoma, and consented for their surgical tissue to be used for research at Royal Hobart Hospital. Twenty 
patients had demonstrated mild-moderate, Global Initiative for Obstructive Lung Disease (GOLD) stage I and 
II COPD of which nine were COPD-CS and eleven COPD-ES (>1year smoking cessation). Eleven individuals 
NLFS. Ten non-smoking tissues were obtained from the James Hogg Lung Registry, the University of British 
Columbia with approval from the Providence Health Care Research Ethics Board H00–50110, and were included 
as a control group (NC) for comparison. Subjects with other respiratory diseases, a history of recent acute exac-
erbation of COPD and those on systemic or inhaled corticosteroids were excluded from the study. The surgically 
resected material was taken well away from the primary tumor and contained non-cancer affected small airways.
BAL Fluid (BALF). Fifty-four human subjects volunteered for the study. BALF from 13 NLFS, 16 COPD-CS, 
and 14 COPD-ES were compared with 11 NCs. Subjects with recent respiratory disease, infection or acute 
Figure 6. Representative pictures (400x) of M1 AMs dual stained for iNOS (brown) and CD68 (blue); (a) 
Normal control, and (b) COPD-CS, counterstained with nuclear fast red (pink). M2 phenotype macrophages 
stained brown with CD163 and arginase-1(ARG-1), (c,e) Normal controls and (d,f) COPD-CS respectively, 
with nuclear-stained hematoxylin (blue).
www.nature.com/scientificreports/
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exacerbation of COPD and those on systemic or inhaled corticosteroids were excluded from the study. BALF 
was obtained and processed as described previously (14, 15). Once extracted the BALF was transported to the 
laboratory at 4 °C for processing and analysis. Total cell counts were determined on the extracted unfiltered BALF 
Figure 7. AMs numbers in BAL. (a) Total AMs, (b) M1 and (c) M2 macrophages in NC, NLFS COPD-CS, 
and ES. (d) Represent percent of total macrophage for each phenotypic population (Data in median and range; 
***p < 0.001, *p < 0.05).
Figure 8. Regression analysis for BAL AMs with lung function in COPD groups. (a) Total AMs and (b) M2 
AMs.
www.nature.com/scientificreports/
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using a hemocytometer, and further 200 µL of the BALF was cytocentrifuged at 100 g for 5 min to produce two 
cytospots on a glass slide. BAL cytospins were fixed in formalin for 10 minutes before staining. BALF supernatants 
were prepared by filtering the BALF through a 200-micron mesh and centrifuging at 250 g for 15 min at 4 °C to 
remove cell debris. Aliquots of the BALF supernatants were stored at −80 °C until used.
Immunohistochemistry. Resected tissue was formalin fixed, paraffin embedded, tissue sections were cut at 
3.5-micron thickness, and were dewaxed and rehydrated in ethanol. Further, both BAL cytospins and the resected 
tissues underwent heat retrieval and endogenous peroxidase activity blocked with 3% hydrogen peroxide for 
10 minutes.
For M1 macrophages, resected tissues and BALF cytospins were dual stained with mouse anti-CD68 mono-
clonal antibody (KP1, Dako, M0814, 1/400 dilution) and a rabbit anti-iNOS polyclonal antibody (Thermo Fisher 
Australia, PA1–21054, 1/100 dilution). Bound iNOS antibodies were elaborated using peroxidase-labelled Rabbit 
Envision + and visualized as brown using 3-3′-Diaminobenzidine (DAB) (K3468; Dako Denmark A/S), while 
CD68 antibodies were developed using Dako REAL detection system (K5005; Dako) and visualized as blue with 
BCIP/NBT (5-bromo-4-chloro-3′-indolyphosphate and nitro-blue tetrazolium) (K0598; Dako) in a ready-made 
Figure 9. Cytokine profiles in BAL of NC, NLFS, COPD-CS and ES: (a) M1, (b) M2, (c) inflammatory 
cytokines (IL-6, IL-1β and TNFα) (d) IL-12/IL-4 ratio.
Figure 10. Positive correlation of M2 macrophages with (a) CCL22 and (b) IL-4 in COPD-CS.
www.nature.com/scientificreports/
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substrate system. Endogenous alkaline phosphatase activity was inhibited by the addition of Levamisole (X3021; 
Dako). Further, the slides were counterstained with nuclear fast red to visualize pink nuclei. Single stained 
CD68 + cells negative for iNOS were considered as the M0 cell population.
To characterize M2 macrophages, CD163s and Arginase-1 staining were performed using mouse anti-CD163 
(EDHu-1, AbD Serotec, MCA1853, 1/100 dilution) anti-Arg1 (BD Biosciences, 610708, 1/100 dilution) anti-
bodies, for 90 minutes. Bound CD163 and Arg1 antibodies were elaborated using peroxidase-labelled mouse 
Envision + (Dako Denmark), developed with DAB and were counterstained with hematoxylin.
Image Analysis. Computer-assisted image analysis was performed with a Leica DM 2500 microscope and 
Leica DFC495 camera and Image Pro Plus 7.0 software. Five random fields selection of small airways less than 
two mm in thick (a minimum of two airways per subject) were chosen for comprehensive analysis without ad 
hoc area selection, although muscle bundles and glands were excluded from the area surveyed. Small airways 
sub-epithelium up to 100 microns deep were quantitated. Stained M0, M1 and M2 cells in the sub-epithelium and 
epithelium were separately counted and is presented here as per mm2 of the area surveyed and per mm of reticu-
lar basement membrane (RBM) length respectively. For Arg-1 expression, separate analysis was done for the total 
sub-epithelium (excluding muscle areas) and epithelium and further, the data here is represented as percent of 
tissue Arg-1 expression.
BAL cells counts were done using brightfield microscope (Olympus BX53) assisted by Visiopharm new-
CAST™ software. An automated motorized system provided an unbiased uniform random area sampling for 12 
fields per cytospot, and stained cells were manually counted for each selected field. Counts were normalized with 
BAL dilution factor and presented here as cells per ml of the original BAL sample.
Cytokine Analysis. Cell-free BALF supernatants were thawed on ice and concentrated ten fold, using 3 kDa 
cutoff Amicon® Ultra-4 Centrifugal Filter Units (UFC800308 Merck Millipore) and centrifugation (2000g, 
Figure 11. Fold changes in mRNA levels of M1 and M2 chemokines in the lungs of mice chronically exposed to 
cigarette smoke for (a) six and (b) eight weeks and normal air exposed controls (**p < 0.0.01; *p < 0.05).
Groups NC NLFS COPD-CS COPD-ES
Tissue source BAL SA BAL SA BAL SA BAL SA
Subjects (n) 11 10 13 11 16 9 13 11
Age (years) 44 (20–68) 68 (63–75) 50 (30–66) 70 (52–79) 61 (46–78) 64 (59–78) 62 (53–69) 68 (56–85)
Smoking (Pack-Years) 0 0 32 (10–57) 33 (3–60) 45 (18–78) 28.5 (2–50) 51 (18–150) 33 (18–36)
FEV1 /FVC (post BD)† 82 (71–88) N/A 77 (70–96) 76 (70–90) 59 (46–68) 66 (60–70) 57 (38–68) 64 (55–69)
Table 1. Demographic details and lung function data for participants. Data represented here as median and 
range in brackets. NC- Normal non-smoker controls, NLFS- Normal Lung Function Smokers, COPD-CS- 
COPD-Current Smokers and COPD-ES- COPD-Ex Smoker. BAL- Bronchoalveolar Lavage; SA- Small Airways 
from resected tissues. FEV1/FVC- Ratio of the forced expiratory volume in the first one second to the forced 
vital capacity of the lungs. †Post BD values after 400 µg of salbutamol. N/A- Not Available.
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30 min, 4 °C). Human cytokines for M1/proinflammatory cytokines (IL-12, IFNγ, IL-1β and TNFα) and M2 (IL-
4, IL-13, CCL22, IL-10, IL-6) macrophages were quantitated using multiplexing (MPHCYTOMAG60; Millipore 
Multiplex kits), and analysis was done using Luminex™ MagPix Multiplex technology platform according to 
manufacturer instructions. Chemokine/cytokine quantitation was derived from the standard curve and repre-
sented here as picograms per ml of original BAL sample.
mRNA analysis of mouse lung. Mice were exposed through the nose-only to the smoke of 12 research 
grade cigarettes, for one hour, twice per day, five days per week, for six weeks20,21,28. This equates to a pack-a-day 
human smoker. When early features of COPD developed after six weeks, lung mRNA was extracted, and microar-
rays performed using Affymetrix GeneChips. GeneSpring analysis was employed to assess the mRNA transcript 
levels of M1 (IP10, IFN-γ, IL-12) and M2 markers (CCL22, IL-4Rα, IL-13Rα).
Statistical analysis. Following a check for normal distribution, the analysis here is represented as median 
and range, non-parametric (Kruskal–Wallis) analysis of variance with multiple comparisons using Dunn’s test. 
Linear regression and Pearson or Spearman r’ was used for correlation analysis. Mouse data were analyzed using 
unpaired t-tests assuming Gaussian distribution with PRISM V6.0d software (GraphPad, La Jolla, CA, USA), and 
are presented as means ± SEM of 4–8 mice/group, p < 0.05 was considered statistically significant.
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